JCO

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  

JCO
Mar 18, 2025, 16:54 | Positive
The launch of the official JCO Journals LinkedIn page
JCO Journals shared a post on LinkedIn: "We're thrilled to announce the launch of the…
Feb 3, 2025, 14:40 | Blog
Paolo Tarantino: Fixed dose of capecitabine vs standard dose for Metastatic Breast Cancer
Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, posted on X about recent paper…
Feb 3, 2025, 14:01 | Blog
Vivek Subbiah: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, posted on…
Jan 25, 2025, 16:19 | Science
Paolo Tarantino: Evolutions in the treatment of HER2+ breast cancer
Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute, shared an article by Tess A. O'Meara…
Dec 27, 2024, 08:06 | Science
The Economic Impact of Novel Oncology Drug Coverage Through Patient Assistance Programs - JCO Oncology Practice
JCO Oncology Practice shared an article by Vanessa Mara Samuel on X: "Evaluating the Economic…
Dec 23, 2024, 12:23 | Science
Paolo Tarantino: PostMONARCH is out in Journal of Clinical Oncology
A recent paper by Kevin Kalinsky, Director of the Glenn Family Breast Center at Winship,…
Dec 22, 2024, 15:33 | Oncolibrary
New Paper Alert! HR+ Breast Cancer: Efficacy of Subsequent Treatments After CDK4/6 Inhibitor Progression
New Paper Published in JCO Oncology Practice on Dec 17, 2024 on HR+ Breast Cancer…
Dec 19, 2024, 11:54 | Opinion
Lung Cancer Trial Highlights from 2024 By Yakup Ergün
Yakup Ergün, Medical Oncologist at Antalya City Hospital, posted on X: “What happened in Lung…
Nov 18, 2024, 12:54 | Insight
Ovarian Function Suppression in Premenopausal Women With Breast Cancer
Dario Trapani, Medical oncologist at the European Institute of Oncology (IEO), shared a post by…
Oct 26, 2024, 10:44 | Blog
Laura Vater: JCO podcast about grief and the power of colleagues who support one another
Laura Vater, Gastrointestinal oncologist at the IU Simon Comprehensive Cancer Center, shared a post on…
Oct 25, 2024, 14:25 | Insight
Aaron Mitchell: New findings on cancer care quality for low-income Medicare patients
Aaron Mitchell, Medical Oncologist and Health Services Researcher at Memorial Sloan Kettering Cancer Center, shared…
Oct 18, 2024, 16:33 | Blog
Jonathan Friedberg: End Point Surrogacy in First-Line CLL
Jonathan Friedberg, Director of Wilmot Cancer Institute, posted the following on X: “End Point Surrogacy in…
Oct 15, 2024, 16:40 | Insight
First-Line Procarbazine, CCNU, and Vincristine With Radiotherapy in IDH-Mutant Oligodendroglioma - Journal of Clinical Oncology
Journal of Clinical Oncology shared a post on X: "Survival Outcomes Associated With First-Line Procarbazine, CCNU,…
Oct 13, 2024, 22:27 | Insight
Stephen Liu: Analysis of locoregional relapse after segmentectomy in JCOG0802
Stephen Liu shared a post on X: “Analysis of locoregional relapse after segmentectomy in JCOG0802.…
Oct 13, 2024, 11:05 | Insight
Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology - JCO Oncology Practice
JCO Oncology Practice shared a post on X: "Guide to Understanding and Supporting International Medical Graduates…
Oct 13, 2024, 10:44 | Insight
Sharlene Gill: Duration of adjuvant treatment in Stage III colon cancer
Sharlene Gill shared a post on X: "Duration of adjuvant treatment in s3 colon cancer in…
Oct 11, 2024, 17:58 | Insight
Jarushka Naidoo: Randomized Phase II Trial Osimertinib with or without Ramucirumab in 1st line EGFR+NSCLC
Jarushka Naidoo shared a post on X: "RAMOSE: Randomized Ph II Trial Osimertinib+/-Ramucirumab in 1L EGFR+…
Oct 11, 2024, 17:21 | Insight
Xiuning Le: Phase 2 RAMOSE osimertinib with or without ramucrimab in 1L EGFR+ NSCLC
Xiuning Le shared a post on X: "Newly online Journal of Clinical Oncology. Our randomized phase…
Oct 9, 2024, 16:50 | Insight
Ghassan Abou-Alfa: ERBB2-altered gallbladder cancer characterization in Chile
Ghassan Abou-Alfa, Medical Oncologist, Memorial Sloan Kettering Cancer Center, shared a post on X: "Congratulations…
Oct 8, 2024, 15:41 | Insight
Elisa Agostinetto: Association between hormonal contraceptives and breast cancer risk in BRCA1 carriers
Elisa Agostinetto shared a post on X: “Out in Journal of Clinical Oncology: A pooled…
Oct 8, 2024, 10:16 | Blog
The Cancer Alliance call to ACT NOW for Close The Equity Gap to Leave No One Behind
Salome Meyer, Independent Consultant at Private, shared a post by Sharon Kapambwe, Technical Officer of…
Oct 3, 2024, 12:54 | Insight
Article of the Week, Suggested by the BPDCN International Registry
Immune Oncology Research Institute shared a post on LinkedIn: “Article of the Week Suggested by the…
Sep 29, 2024, 18:45 | Insight
Ishwaria Subbiah: Understanding what goal concordant care truly means
Ishwaria Subbiah shared a post on LinkedIn: "Goal-Concordant Care Now out in Journal of Clinical Oncology …
Sep 27, 2024, 13:30 | Insight
Yüksel Ürün: Adjuvant nivolumab vs placebo in localized RCC patients at high recurrence risk post-nephrectomy by Robert J. Motzer
Yüksel Ürün shared a post on X: "CheckMate 914 (Part B) failed to show DFS improvement…
Sep 19, 2024, 14:33 | Insight
Prognostic Perception and Quality of Life in Patients with Metastatic Renal and Bladder Cancer
JCO Global Oncology shared a post on X: “Perceptions and Expectations: A Study on Prognostic…
Sep 12, 2024, 09:48 | Insight
Datopotamab deruxtecan vs docetaxel for previously treated advanced NSCLC
Erman Akkus shared a post on X about a recent paper by Myung-Ju Ahn et…
Sep 11, 2024, 16:34 | Insight
Andrea Necchi: Our next piece of the neoadjuvant puzzle in muscle-invasive bladder cancer
Andrea Necchi, Associate Editor at Journal of Clinical Oncology, shared a post on X about…
Sep 2, 2024, 08:40 | Insight
Durable Responses to Atezolizumab Plus Bevacizumab in HCC
Saadvik Raghuramy shared a post on X about a recent paper by Ying-Chun Shen et…
Sep 2, 2024, 03:14 | Insight
Othman Al-Sawaf: Surrogacy of endpoints in 1L CLL trials
Othman Al-Sawaf, Haematologist and Medical Oncologist at the University Hospital Cologne, Cologne, Germany, shared a…
Sep 1, 2024, 20:21 | Blog
Andrea Necchi: MRI should be a routine for daily management of MIBC
Andrea Necchi, Associate Editor at Journal of Clinical Oncology, shared Nick James's, Professor of Prostate…
Aug 29, 2024, 03:06 | Blog
Mark Lewis: We’re accepting submissions for JCO Oncology Advances
Mark Lewis shared on X: "Calling all oncology researchers! We’re accepting submissions for JCO Oncology…
Aug 25, 2024, 14:15 | Insight
JCO Study Confirms Annual Mammograms Improve Breast Cancer Outcomes Across All Demographics
American Society of Clinical Oncology (ASCO) shared a post on LinkedIn about a recent paper…
Aug 4, 2024, 23:39 | Insight
HERALD EPOC1806 study explores trastuzumab deruxtecan in solid tumors with HER2 amplification by ctDNA
Stephen Liu shared a post on X: "HERALD EPOC1806 study published in JCO explored trastuzumab…
Jul 28, 2024, 07:13 | Insight
William Schpero: There are long-standing disparities in clinical trial participation in the United States
William Schpero, assistant professor in the Division of Health Policy and Economics of the Department…
Jul 26, 2024, 00:16 | Insight
Impact of the intratumoral microbiome of NSCLC on outcomes with immunotherapy
Stephen Liu shared on X: "Impressive work on impact of the intratumoral microbiome of NSCLC…
Jul 26, 2024, 00:03 | Blog
Elisa Agostinetto: Must-read by Marleen Kok on the limitations of KEYNOTE-522
Elisa Agostinetto shared on X: "Out in JCO a must-read by Marleen Kok on the…
Jul 13, 2024, 22:16 | Insight
Erman Akkus: Management of cancer-related fatigue - ASCO guideline
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X about a…
Jul 6, 2024, 12:24 | Career
Omnia Korani: I have been accepted into the JCO Trainee Reviewer Mentoring Program
Omnia Korani, Assistant Lecturer at the National Cancer Institute, shared a post on LinkedIn: "Exciting…
Jul 5, 2024, 13:47 | Insight
Andrea Apolo: Very proud of this Clinical Trial of Cabozantinib/Nivolumab published at JCO
Shilpa Gupta shared a post by Andrea Apolo, adding: "Huge congrats Andrea Apolo, leading this…
Jul 3, 2024, 22:59 | Blog
Aleix Prat: Our 2 articles published this week
Aleix Prat, Head of the Medical Oncology Department at Hospital Clínic Barcelona, shared on X:…
Jul 3, 2024, 14:37 | Insight
Jarushka Naidoo: Phase III RESILIENT Trial of Liposomal Irinotecan v Topotecan in 2L SCLC
Jarushka Naidoo shared a post on X: “Phase III RESILIENT Trial of Liposomal Irinotecan v…
Jul 1, 2024, 15:23 | Insight
Paolo Tarantino: Final analysis of the ATEMPT phase 2 trial
Paolo Tarantino shared a post on X: “Can ADCs help prevent recurrence from breast cancer…
Jun 21, 2024, 14:36 | Insight
High ORR and low CRS rate with Linvoseltamab for R/R Multiple Myeloma
Recently Jeffrey Zonder shared a post on X about a recent paper by Naresh Bumma…
Jun 21, 2024, 10:50 | Blog
Out in JCO the groundbreaking results of the randomized phase 3 trial PALOMA-3 study
Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared on LinkedIn: "Out in…
May 16, 2024, 14:15 | Insight
Elie G. Dib: Excited to share the results of the TAPUR study
Elie G. Dib, Associate Director of the Haematology-Oncology Training Program at Saint Joseph Mercy Hospital,…
May 12, 2024, 07:40 | Insight
Yüksel Ürün: Excellent research on plasma Kidney Injury Molecule-1
Yüksel Ürün shared on X: "Congratulations to Wenxin Xu and the team for their excellent…
May 12, 2024, 04:15 | Blog
Nico Gagelmann: Big achievement in JCO on timing of transplantation for patients with MDS
Nico Gagelmann, Chair of CAR-T for Plasma Cell Disorder Committee and Chair Trainee Committee at The…
May 9, 2024, 12:42 | Blog
Estela Rodriguez: So much work to do to address barriers and develop pragmatic trials
Estela Rodriguez shared on X: “Only 7.1% of patients with cancer participate in clinical trials- so…
Apr 19, 2024, 15:52 | Drugs
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer based on ALINA trial
FDA, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc.) for adjuvant treatment following…
Apr 8, 2024, 22:37 | Insight
Key Message Highlights from Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma
Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous…
Mar 28, 2024, 02:31 | Insight
Rami Manochakian: New Supportive Care Guideline by ASCO on Vaccination of adult with cancer
Rami Manochakian, Thoracic Medical Oncologist at Mayo Clinic, shared a post on X: "Hot off…
Mar 16, 2024, 10:45 | Drugs
Vivek Subbiah: Exceptional Responses to Selpercatinib in RET Fusion–Driven Metastatic Pancreatic Cancer
Vivek Subbiah recently shared a post on X/Twitter: “Exceptional Responses to Selpercatinib in RET Fusion–Driven…
Mar 3, 2024, 17:26 | Insight
Anjali Sibley: Let’s Harness the Healing Power - The Benefits of Exercise and Physical Activity During Cancer Treatment
Anjali Sibley, Clinical Associate Professor of Medicine at Stanford University School of Medicine, shared a…
Jan 29, 2024, 10:53 | Insight
Paolo Tarantino: The highly debated results of PALOMA2 now published on JCO
Paolo Tarantino, Medical Oncologist, PhD Università degli Studi di Milano, Research Dana-Farber Cancer Institute, Harvard…
Dec 12, 2023, 11:42 | Insight
Shruti Jolly: Treating lung cancer with immunotherapy and radiation without chemotherapy
Shruti Jolly, Associate Director for the Statewide Cancer Network at Michigan Medicine, shared on LinkedIn:…
May 28, 2023, 16:27 | Opinion
As an oncology community we still have a lot to do, that more and more children do not need to go into the palliative care clinic and get cured - Gevorg Tamamyan
Quoting Gevorg Tamamyan on LinkedIn, "When people ask me, isn't it difficult to work as…
All: 56 Posts: 1 - 100
Special Coverage